Find clinical trials

The purpose of this Expanded Access Program (EAP) is to provide continued access to LP352, an Investigational Medicinal Product (IMP), which has no marketing authorisations anywhere in the world and which is being investigated in patients with Developmental and Epileptic Encephalopathies (DEEs). Within Australia, the EAP will; allow participants of LP352-201 and LP352-202 (approved by CHQ HREC, QCH lead site) to continue to access this treatment after the participant has successfully completed the LP352-202 trial (rollover patient), or provide treatment for an immediate family member of a participant that completed the LP352-202 trial who has the exact same gene mutation resulting in the same DEE phenotype (nave participant).

This is a global Phase 3 double-blind, randomized, Placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with Dravet syndrome. Randomisation will be stratified by 4 categories of age (2 to 5 years, 6 to 11 years, 12 to 17 years, and 18 to 65 years) and 2 categories of country region categories (Asian, not Asian). The study consists of the following periods for all participants: Screening (approximately 5 weeks), Titration (3 weeks or Days 1 to 21), and Maintenance (12 weeks or Days 22 to 105). Participants not entering the open-label extension (OLE) will complete Taper (up to 2 weeks) and Follow-up (4 weeks after completing Taper).

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The main objective of this study is to evaluate if those participants who received amlitelimab dose 1 in the parent studies (EFC17559 [COAST-1], EFC17560 [COAST 2], EFC17561 [SHORE]) and were responders can maintain their response either remaining at dose 1 or switching to dose 2 of amlitelimab compared to treatment withdrawal.

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease state will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Multiple doses of etentamig in combination with iberdomide will be explored. Each treatment arm receives a different dose of etentamig and iberdomide to determine a tolerable dose. Approximately 135 adult participants with R/R MM will be enrolled in the study in approximately 50 sites worldwide. In phase 1 participants will receive escalating intravenous (IV) etentamig in combination with oral iberdomide. In phase 2 participants will receive IV etentamig at one of two doses in combination with oral iberdomide, as part of the approximately 129 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and and monitoring of side effects.